Literature DB >> 27008969

Melanoma addiction to the long non-coding RNA SAMMSON.

Eleonora Leucci1,2, Roberto Vendramin1,2, Marco Spinazzi2, Patrick Laurette3, Mark Fiers2, Jasper Wouters4, Enrico Radaelli5, Sven Eyckerman6,7, Carina Leonelli8,9, Katrien Vanderheyden8,9, Aljosja Rogiers1,2, Els Hermans10, Pieter Baatsen2, Stein Aerts11, Frederic Amant10, Stefan Van Aelst12,13, Joost van den Oord4, Bart de Strooper2, Irwin Davidson3, Denis L J Lafontaine14, Kris Gevaert6,7, Jo Vandesompele8,9, Pieter Mestdagh8,9, Jean-Christophe Marine1,2.   

Abstract

Focal amplifications of chromosome 3p13-3p14 occur in about 10% of melanomas and are associated with a poor prognosis. The melanoma-specific oncogene MITF resides at the epicentre of this amplicon. However, whether other loci present in this amplicon also contribute to melanomagenesis is unknown. Here we show that the recently annotated long non-coding RNA (lncRNA) gene SAMMSON is consistently co-gained with MITF. In addition, SAMMSON is a target of the lineage-specific transcription factor SOX10 and its expression is detectable in more than 90% of human melanomas. Whereas exogenous SAMMSON increases the clonogenic potential in trans, SAMMSON knockdown drastically decreases the viability of melanoma cells irrespective of their transcriptional cell state and BRAF, NRAS or TP53 mutational status. Moreover, SAMMSON targeting sensitizes melanoma to MAPK-targeting therapeutics both in vitro and in patient-derived xenograft models. Mechanistically, SAMMSON interacts with p32, a master regulator of mitochondrial homeostasis and metabolism, to increase its mitochondrial targeting and pro-oncogenic function. Our results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27008969     DOI: 10.1038/nature17161

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

Review 1.  Sox proteins in melanocyte development and melanoma.

Authors:  Melissa L Harris; Laura L Baxter; Stacie K Loftus; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2010-04-22       Impact factor: 4.693

2.  p32 regulates mitochondrial morphology and dynamics through parkin.

Authors:  Y Li; O W Wan; W Xie; K K K Chung
Journal:  Neuroscience       Date:  2011-10-10       Impact factor: 3.590

3.  Chaperone-like protein p32 regulates ULK1 stability and autophagy.

Authors:  H Jiao; G-Q Su; W Dong; L Zhang; W Xie; L-M Yao; P Chen; Z-X Wang; Y-C Liou; H You
Journal:  Cell Death Differ       Date:  2015-04-23       Impact factor: 15.828

4.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

Authors:  Francisca Vazquez; Ji-Hong Lim; Helen Chim; Kavita Bhalla; Geoff Girnun; Kerry Pierce; Clary B Clish; Scott R Granter; Hans R Widlund; Bruce M Spiegelman; Pere Puigserver
Journal:  Cancer Cell       Date:  2013-02-14       Impact factor: 31.743

Review 5.  Links between metabolism and cancer.

Authors:  Chi V Dang
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

6.  A mitochondrial ribosomal and RNA decay pathway blocks cell proliferation.

Authors:  Uwe Richter; Taina Lahtinen; Paula Marttinen; Maarit Myöhänen; Dario Greco; Giuseppe Cannino; Howard T Jacobs; Niina Lietzén; Tuula A Nyman; Brendan J Battersby
Journal:  Curr Biol       Date:  2013-02-28       Impact factor: 10.834

7.  Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation.

Authors:  Valentina Fogal; Adam D Richardson; Priya P Karmali; Immo E Scheffler; Jeffrey W Smith; Erkki Ruoslahti
Journal:  Mol Cell Biol       Date:  2010-01-25       Impact factor: 4.272

8.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

9.  Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.

Authors:  Valentina Fogal; Ivan Babic; Ying Chao; Sandra Pastorino; Rajesh Mukthavaram; Pengfei Jiang; Yoon-Jae Cho; Sandeep C Pingle; John R Crawford; David E Piccioni; Santosh Kesari
Journal:  Oncotarget       Date:  2015-01-20

10.  p32/gC1qR is indispensable for fetal development and mitochondrial translation: importance of its RNA-binding ability.

Authors:  Mikako Yagi; Takeshi Uchiumi; Shinya Takazaki; Bungo Okuno; Masatoshi Nomura; Shin-ichi Yoshida; Tomotake Kanki; Dongchon Kang
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

View more
  211 in total

1.  miRNA displacement as a promising approach for cancer therapy.

Authors:  David Gilot; Marie-Dominique Galibert
Journal:  Mol Cell Oncol       Date:  2017-12-11

Review 2.  Long noncoding RNAs in the metabolic control of inflammation and immune disorders.

Authors:  Junfang Xu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2018-05-23       Impact factor: 11.530

3.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

4.  M(R)apping RNA-Protein Interactions.

Authors:  Jasmine Barra; Roberto Vendramin; Eleonora Leucci
Journal:  Methods Mol Biol       Date:  2021

5.  Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway.

Authors:  Xiangjun Chen; Hao Dong; Sha Liu; Li Yu; Dexiong Yan; Xingwei Yao; Weijing Sun; Dezhi Han; Guozhen Gao
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 6.  Non-coding RNAs: the dark side of nuclear-mitochondrial communication.

Authors:  Roberto Vendramin; Jean-Christophe Marine; Eleonora Leucci
Journal:  EMBO J       Date:  2017-03-17       Impact factor: 11.598

7.  A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Authors:  Karen Verboom; Wouter Van Loocke; Pieter-Jan Volders; Bieke Decaesteker; Francisco Avila Cobos; Simon Bornschein; Charles E de Bock; Zeynep Kalender Atak; Emmanuelle Clappier; Stein Aerts; Jan Cools; Jean Soulier; Tom Taghon; Pieter Van Vlierberghe; Jo Vandesompele; Frank Speleman; Kaat Durinck
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 8.  Mechanisms and consequences of subcellular RNA localization across diverse cell types.

Authors:  Krysta L Engel; Ankita Arora; Raeann Goering; Hei-Yong G Lo; J Matthew Taliaferro
Journal:  Traffic       Date:  2020-04-29       Impact factor: 6.215

9.  The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Authors:  Cibele Cardoso; Rodolfo B Serafim; Akinori Kawakami; Cristiano Gonçalves Pereira; Jason Roszik; Valeria Valente; Vinicius L Vazquez; David E Fisher; Enilza M Espreafico
Journal:  Pigment Cell Melanoma Res       Date:  2018-12-16       Impact factor: 4.693

10.  LncUBE2R2-AS1 acts as a microRNA sponge of miR-302b to promote HCC progression via activation EGFR-PI3K-AKT signaling pathway.

Authors:  Zhe Wu; Zhi-Hong Wei; Shao-Hua Chen
Journal:  Cell Cycle       Date:  2020-08-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.